Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain
- PDF / 3,309,946 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 61 Downloads / 198 Views
ORIGINAL ARTICLE
Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain Andreas H. Kramer • Craig Jenne • Jessalyn K. Holodinsky • Stephanie Todd Derek J. Roberts • Paul Kubes • David A. Zygun • Michael D. Hill • Caroline Leger • John H. Wong
•
Ó Springer Science+Business Media New York 2015
Abstract Background Intraventricular hemorrhage (IVH) frequently complicates spontaneous intracerebral or subarachnoid hemorrhage (SAH). Administration of intraventricular tissue plasminogen activator (TPA) accelerates blood clearance, but optimal dosing has not been clarified. Using a standardized TPA dose, we assessed peak cerebrospinal fluid (CSF) TPA concentrations, the rate at which TPA clears, and the relationship between TPA concentration and biological activity. Methods Twelve patients with aneurysmal SAH and IVH, treated with endovascular coiling and ventricular drainage, A. H. Kramer (&) C. Jenne J. K. Holodinsky S. Todd P. Kubes D. A. Zygun Department of Critical Care Medicine, University of Calgary, McCaig Tower, 3134 Hospital Drive N.W, Calgary, AB T2N 2T9, Canada e-mail: [email protected] A. H. Kramer D. A. Zygun M. D. Hill J. H. Wong Department of Clinical Neurosciences, University of Calgary, Calgary, Canada C. Jenne P. Kubes Calvin, Phoebe & Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada J. K. Holodinsky D. J. Roberts D. A. Zygun M. D. Hill Department of Community Health Sciences, University of Calgary, Calgary, Canada D. J. Roberts Department of Surgery, University of Calgary, Calgary, Canada D. A. Zygun Department of Medicine, University of Alberta, Alberta, Canada C. Leger University of Laval, Quebec, Canada
were randomized to receive either 2 mg intraventricular TPA or placebo every 12 h (five doses). CT scans were performed 12, 48, and 72 h after initial administration, and blood was quantified using the SAH Sum and IVH Scores. CSF TPA and fibrin degradation product (D-dimer) concentrations were measured at baseline and 1, 6, and 12 h after the first dose using ELISA assays. Results Median CSF TPA concentrations in seven TPAtreated patients were 525 (IQR 352–2129), 323 (233–413), and 47 (29–283) ng/ml, respectively, at 1, 6, and 12 h after drug administration. Peak concentrations varied markedly (401–8398 ng/ml). Two patients still had slightly elevated levels (283–285 ng/ml) when the second dose was due after 12 h. There was no significant correlation between the magnitude of CSF TPA elevation and the rate of blood clearance or degree of D-dimer elevation. D-dimer peaked at 6 h, had declined by 12 h, and correlated strongly with radiographic IVH clearance (r = 0.82, p = 0.02). Conclusions The pharmacokinetics of intraventricular TPA administration varies between individual patients. TPA dose does not need to exceed 2 mg. The optimal administration interval is every 8–12 h. Keywords Intraventricular hemorrhage Subarachnoid hemorrhage Tissue plasminogen activa
Data Loading...
